Drug safety outsourcing varies among similar sized firms

By Nick Taylor

- Last updated on GMT

Related tags: Outsourcing, Employment

More than 50 per cent of large pharma keep all pharmacovigilance in-house but among smaller firms, and even some big businesses, outsourcing is considerable, according to a new report.

Outsourcing pharmacovigilance can help companies manage workloads, tap expertise and remove the need to add in-house capacity. Despite these benefits, 56 per cent of large pharma companies polled by Cutting Edge Information (CEI) ​keep all pharmacovigilance in-house.

In a report​ CEI explains that large pharma companies’ strong technology infrastructure and ability to attract qualified, experienced employees limit their outsourcing. Also, these firms’ portfolios, pipelines and resources make keeping pharmacovigilance in-house practical and feasible.

However, even among large pharma companies outsourcing can account for a significant proportion of pharmacovigilance budget. The report cites a large pharma company which outsources 50 per cent of its pharmacovigilance activities.

Also, a pharma company, which outsources 15 per cent of pharmacovigilance, explains that it uses vendors for risk evaluation and mitigation strategies (REMS). The firm reasons that it is uneconomical to employ a full-time REMS specialist who will only be needed a few times a year.

Every small company polled outsources some of their pharmacovigilance work but the amount varies from 10 per cent up to 80 per cent. Consequently, although in general smaller firms outsource more, there is no consistent standard even among similar sized companies.

Vendor offerings

The poll also looks at companies preferences for outsourcing to vendors who provide turnkey or ad hoc ​services. Of the large companies polled, 50 per cent choose to outsource each activity separately.

These businesses already have a pharmacovigilance infrastructure in place and use vendors to deal with spikes in demand. This removes the need to hire and fire in-house employees.

In contrast, small and medium sized firms prefer outsourcing partners that can provide turnkey and ad hoc ​services. The report believes that the flexibility offered by these vendors is attractive to pharmacovigilance departments facing constantly changing workloads and resources.

Related news

Related products

show more

Local Lab Data Management

Local Lab Data Management

Q2 Solutions | 01-Jul-2020 | Technical / White Paper

When a clinical trial requires local or point-of-care laboratory testing, managing the resulting data can be a significant burden to both the sponsor and...

Laboratory Solutions for COVID-19 Clinical Trials

Laboratory Solutions for COVID-19 Clinical Trials

Q2 Solutions | 10-Jun-2020 | Clinical Study

As a leading laboratory services organization for trials across the globe, we are proud to partner with clients to support COVID-19 clinical trials. Our...

Parents as Gatekeepers for Children with Cancer

Parents as Gatekeepers for Children with Cancer

PRA Health Sciences | 08-Jun-2020 | Technical / White Paper

The RACE for Children Act will require new drugs intended for adult cancer treatment to also be studied in pediatric cancers when the molecular target...

RACE Act Prompts Pediatric Oncology Trials

RACE Act Prompts Pediatric Oncology Trials

PRA Health Sciences | 04-May-2020 | Technical / White Paper

Many providers prescribe drugs off-label to pediatric patients, even though there have been few pediatric trials for many of these drugs. In response,...

Related suppliers

Follow us


View more